Sage Therapeutics Inc

-0.08 (-0.19%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)2.44B
Current PE3.83
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$2.08 Million
Adjusted EPS-$1.81
See more estimates
10-Day MA$44.03
50-Day MA$56.86
200-Day MA$72.84
See more pivots

Sage Therapeutics Inc Stock, NASDAQ:SAGE

215 1st Street, Cambridge, Massachusetts 02142
United States of America
Phone: +1.617.299.8380
Number of Employees: 298


SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.